Coronavirus disease 2019 (COVID-19) refers to a group of respiratory illnesses caused by infection with the SARS-CoV-2 virus. Since the emergence of the initial Alpha variant, multiple significant variants have been identified.
Common clinical manifestations
Coughing
Sneezing
Fatigue
Muscle or body aches
Shortness of breath
Changes or loss in taste or smell
Individuals at increased risk for severe illness
The federally declared public health emergency for COVID-19 in the United States concluded on May 11, 2023.
Diagnostic Criteria
Note: The patient must have an active infection to assign code U07.1, COVID-19, for inpatients.
Treatment
Treatment of a COVID infection is primarily focused on symptomatic support of the complications. Specific treatment modalities for severely ill patients include:
| ▸ | High-dose steroids: Dexamethasone |
| ▸ | Antivirals: Remdesivir, Paxlovid |
| ▸ | Monoclonal antibodies |
| ▸ | Tocilizumab (Interleukin-6 receptor blocker) + Dexamethasone |
| ▸ | Baricitinib (immunomodulator) |
CDI & Coding Considerations
Official Coding Guidelines (4/1/2025) state: “For asymptomatic individuals who test positive for COVID-19 and there is no provider documentation of a diagnosis of COVID-19, query the provider as to whether or not the individual has COVID-19.” If the provider documentation does not indicate the hospitalized patient has an active infection (or a previous infection has resolved) and the patient is asymptomatic, the patient no longer has a current (active) COVID infection and code U07.1 would not be assigned.
Sequencing scenarios
When COVID is the principal reason for admission focus of treatment and meets the definition of principal diagnosis, code U07.1 is assigned first, associated manifestations should be included as secondary codes—except when coding guidelines indicate certain diagnoses be sequenced first, such as obstetrics or transplant complications.
When the reason for the admission is a respiratory manifestation associated with COVID, assign code U07.1 as the principal diagnosis and assign Secondary codes for the respiratory manifestations. Providers do not have to explicitly link the respiratory condition with COVID since COVID is a respiratory disease.
Pneumonia associated with COVID, assign U07.1, COVID-19, and J12.82, Pneumonia due to COVID-19. If lower respiratory infection is associated with COVID, assign codes U07.1 and J22. If acute respiratory failure or ARDS, assign U07.1 and J96.00 or J80.
When the reason for the admission is a non-respiratory manifestation (e.g., viral enteritis) due to COVID, assign code U07.1, COVID-19, as the principal diagnosis and assign the code(s) for the manifestation(s) as secondary diagnoses. Provider documentation must link the non-respiratory condition with COVID.
If a patient is admitted with a residual effect (sequelae) of COVID and the provider documentation indicates the COVID infection is inactive or the patient is no longer infectious, assign a code for the residual effect as principal diagnosis and code U09.9, Post COVID-19 condition, as a secondary diagnosis. Code U09.9, establishes a link between a prior COVID infection and post-acute sequela. Code U09.9 cannot be assigned as a principal diagnosis.
The principal diagnosis for a patient presenting with COVID and sepsis (U07.1 or A41.89) depends on the circumstances of the admission and whether sepsis meets the definition of the principal diagnosis. Note that this differs from the coding guidelines for “sepsis and a localized infection” where sepsis is sequenced first.
A patient admitted for COVID during pregnancy, childbirth or the puerperium, assign a code from O98.5-, Other viral diseases complicating pregnancy, childbirth, and the puerperium, as principal diagnosis followed by U07.1 and the appropriate codes for the associated manifestations. However, if the reason for the admission is unrelated to COVID but the patient tests positive for COVID during the admission [and has an active infection], the principal diagnosis is the appropriate codes for the reason for admission, with codes O98.5- and U07.1 assigned as additional diagnoses and the associated COVID manifestations.
Do not assign code U07.1 for possible, probable, or suspected COVID. Instead, code the signs and symptoms reported.
Active vs. resolved infection indicators
Respiratory symptoms, patient placed in isolation, treatment for COVID, e.g., Remdesivir, Dexamethasone, Paxlovid.
No symptoms, greater than 14 days since onset of symptoms or date of positive test, patient not in isolation, lack of COVID treatment (Remdesivir, Decadron, etc.), and provider documentation indicating patient is no longer infectious (“history of COVID”, “non-infectious”, post-COVID condition, etc.). For patients with a history of COVID-19, assign code Z86.16, Personal history of COVID-19.
Query Opportunity
Looking for CDI help?
Learn more about e4health CDI Solutions. Our team is leading the way in the CDI industry.
Need help to earn CEUs or educate your team?
Visit the e4health IQ Education Center and get your free account, or contact us for more information.
CDI Leadership Roundtable
Join e4health’s CDI leaders for our ongoing virtual roundtable series — a forum where CDI professionals come together to explore today’s most relevant industry topics, share real-world insights, and learn from one another. Each session features expert-led discussion on a timely CDI subject, followed by collaborative Q&A. Earn FREE ACDIS CEUs for participating, and visit our roundtable page to see the next scheduled session and register.
What is the e4health CDI Leadership Roundtable?
The goal for the virtual CDI Leadership Roundtable Discussion is for CDI leaders to explore specific topics within CDI, learn about the topic and from each other. During each roundtable, e4health CDI Leader’s will present a CDI topic, spend time sharing current industry standards or some education regarding this topic and then open with probing questions for group discussion.
Who should attend the e4health CDI Leadership Roundtable?
The focus of this group is for those who have influence over CDI program process, policy, and education.
Why should I attend the e4health CDI Roundtable?
This will be a wonderful place to learn, share your wins and challenges and collaborate with other CDI leaders across the industry. Also, after completing a survey, free ACDIS CEUs will be earned.